|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Departments of Pediatrics and Molecular Sciences, Crippled Childrens Foundation Research Center, University of Tennessee; and Methodist LeBonheur Healthcare Foundation, Memphis, TN.
Correspondence to: Michael W. Quasney, MD, PhD, College of Medicine, Department of Pediatrics, Crippled Childrens Foundation Research Center, 50 North Dunlap, Room 301, Memphis, TN 38103
The clinical presentation and outcome following inflammatory
stimuli are determined in part by the type and degree of the stimulus
as well as host factors. We have previously demonstrated associations
between genetic polymorphisms in the regulatory regions of tumor
necrosis factor-
with both the severity of community-acquired
pneumonia (CAP) and the type of clinical presentation. A recent
polymorphism has been described in the gene coding for intracellular
adhesion molecule (ICAM) type 1, which alters a glycine at position 241
to an arginine. This polymorphism is associated with polymyalgia
rheumatica and giant-cell arteritis, common inflammatory diseases
involving the synovium and extracranial branches of the aorta. Both of
these disorders have elevated levels of ICAM-1, and it is hypothesized
that the G241R mutation might allow for more effective binding of
ICAM-1 to Mac-1, thereby enhancing the inflammatory response. We
hypothesized that this mutation may be involved in some of the
complications of CAP in adults.
A prospective cohort study of 289 adults with CAP was performed. Genotyping of the ICAM-1 G241R site was done using allele-specific polymerase chain reaction. Outcome measures included mortality, septic shock (SS), ARDS, and respiratory failure (RF). Heterozygotes at the G241R site demonstrated a frequency of 8.3% in the entire study group; no RR homozygotes were detected.
The frequency of the heterozygotes in patients with SS (6.7%) and RF
(5.7%) was not different from patients without these complications of
CAP. Ten patients in the cohort had ARDS, and 22 patients died; all had
homozygotes for the GG phenotype. We conclude that unlike the
associations we have reported between tumor necrosis factor-
polymorphisms and outcome in patients with CAP, the ICAM-1 polymorphism
that results in the glycine-to-arginine substitution at position 241
does not appear to play a role in SS, RF, ARDS, or mortality in adults
with CAP.
| Footnotes |
|---|
Dr. Quasney is supported in part by the Childrens Foundation of Memphis and by the American Lung Association.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |